-
First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field
December 19, 2014 I Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.
IPH2201-201 is an open label Phase II trial testing IPH2201 as a single agent in a pre-operative setting of squamous cell carcinoma of the oral cavity (OCSCC), a tumor type representative of the larger group of squamous cell cancer of the head and neck.
Dr Jan D Raguse, assistant medical director, Clinic for Oral & Maxillofacial Surgery, Berlin Centre of Reconstructive Surgery, CCCC, and principal investigator of the study, said: “The rationale for this trial is based on the frequent expression of the NKG2A receptor and its ligand, HLA-E, in patients with OSCC”. He added: “The pre-operative setting is very appealing as the absence of prior therapy eliminates confounding effects. This design optimizes our ability to evaluate the antitumor activity of IPH2201. Access to the tumor is another key attractive feature of the study as it will allow a detailed pharmacological evaluation”.
Hervé Brailly, CEO and co-founder of Innate Pharma, said: “We are very enthusiastic to start this first Phase II trial of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field. IPH2201 is exciting because it has the potential to stimulate both the innate and adaptive arms of the immune system to kill tumor cells”. He added: “The CCCC is a reference cancer center with a large experience in the treatment of squamous cell cancer of the head and neck. IPH2201 will be further tested in both hematologic and solid tumors with high level of HLA-E expression”.
The rationale of this trial is based on the expression of NKG2A by both NK and CD8+ cells infiltrating OCSCC (Katou, Ohtani et al. 2007). Binding of IPH2201 to NGK2A blocks the HLA-E driven inhibition of NK and CD8+ cells. HLA-E is expressed in about 80% of patients with squamous cell carcinoma of the head and neck (SSCHN) (Silva 2011; Nasman, Andersson et al. 2013). The resulting stimulation of both the innate and acquired immunity could lead to clinical and pharmacological antitumor activity. In a Phase I dose-escalation safety trial conducted by CCCC, IPH2201 appeared to have a safe and well-tolerated profile.
SOURCE: Innate Pharma
Post Views: 131
-
First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field
December 19, 2014 I Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.
IPH2201-201 is an open label Phase II trial testing IPH2201 as a single agent in a pre-operative setting of squamous cell carcinoma of the oral cavity (OCSCC), a tumor type representative of the larger group of squamous cell cancer of the head and neck.
Dr Jan D Raguse, assistant medical director, Clinic for Oral & Maxillofacial Surgery, Berlin Centre of Reconstructive Surgery, CCCC, and principal investigator of the study, said: “The rationale for this trial is based on the frequent expression of the NKG2A receptor and its ligand, HLA-E, in patients with OSCC”. He added: “The pre-operative setting is very appealing as the absence of prior therapy eliminates confounding effects. This design optimizes our ability to evaluate the antitumor activity of IPH2201. Access to the tumor is another key attractive feature of the study as it will allow a detailed pharmacological evaluation”.
Hervé Brailly, CEO and co-founder of Innate Pharma, said: “We are very enthusiastic to start this first Phase II trial of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field. IPH2201 is exciting because it has the potential to stimulate both the innate and adaptive arms of the immune system to kill tumor cells”. He added: “The CCCC is a reference cancer center with a large experience in the treatment of squamous cell cancer of the head and neck. IPH2201 will be further tested in both hematologic and solid tumors with high level of HLA-E expression”.
The rationale of this trial is based on the expression of NKG2A by both NK and CD8+ cells infiltrating OCSCC (Katou, Ohtani et al. 2007). Binding of IPH2201 to NGK2A blocks the HLA-E driven inhibition of NK and CD8+ cells. HLA-E is expressed in about 80% of patients with squamous cell carcinoma of the head and neck (SSCHN) (Silva 2011; Nasman, Andersson et al. 2013). The resulting stimulation of both the innate and acquired immunity could lead to clinical and pharmacological antitumor activity. In a Phase I dose-escalation safety trial conducted by CCCC, IPH2201 appeared to have a safe and well-tolerated profile.
SOURCE: Innate Pharma
Post Views: 131
